Senators question FDA and FTC over patent and PBM reforms

Zachary Brennan

Senior Editor

Senators may be back in their districts gearing up for next month’s elections, but that isn’t stopping them from questioning both the FDA and Federal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senators question FDA and FTC over patent and PBM reforms

Zachary Brennan

Senior Editor

Sign up to read this article for free.

J&J and Bayer to lay off almost 300 staffers in New Jersey

23andMe CEO says she is no longer open to outside takeover offers

Ron Renaud's new obesity biotech, Kailera, has $400M to go straight to Phase 3

CAMP4, preparing for IPO, announces partnership with BioMarin

GSK’s ViiV stops development of Phase 2 HIV antiviral

3 Tiers for AAV Potency Assay Development Success

Sen­a­tors ques­tion FDA and FTC over patent and PBM re­forms

Zachary Brennan

Senior Editor

Sign up to read this article for free.

J&J and Bay­er to lay off al­most 300 staffers in New Jer­sey

23andMe CEO says she is no longer open to out­side takeover of­fers

Ron Re­naud's new obe­si­ty biotech, Kail­era, has $400M to go straight to Phase 3

CAMP4, prepar­ing for IPO, an­nounces part­ner­ship with Bio­Marin

GSK’s Vi­iV stops de­vel­op­ment of Phase 2 HIV an­tivi­ral

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

Senators question FDA and FTC over patent and PBM reforms

J&J and Bayer to lay off almost 300 staffers in New Jersey

23andMe CEO says she is no longer open to outside takeover offers

Ron Renaud's new obesity biotech, Kailera, has $400M to go straight to Phase 3

CAMP4, preparing for IPO, announces partnership with BioMarin

GSK’s ViiV stops development of Phase 2 HIV antiviral

3 Tiers for AAV Potency Assay Development Success